Australia's TGA tackles backlog of pharma applications for GMP clearance
This article was originally published in SRA
Executive Summary
Recent measures introduced by Australia's Therapeutic Goods Administration to deal with a growing backlog of applications for good manufacturing practice (GMP) clearance for medicines are having a positive impact and are helping to shorten the time it has been taking for the agency to process applications1.